m7G (N7-methylguanosine) Dot Blot Assay Kit

Product Description

The RayBiotech m7G dot blot assay provides a simple and rapid method of quantifying the global m7G levels in RNA/DNA, urine, serum, plasma, or other nucleic samples collected from humans, rats, and mice.

N7-methylguanosine (m7G), is a posttranscriptional modification of RNA that plays an essential role in RNA processing, metabolism, and function. m7G is the most ubiquitous mRNA cap modification and is also present in internal mRNA, microRNA, tRNA, and rRNA. m7G is positively charged and produced by the methyltransferase-like 1 (METTL1) and WD repeat domain 4 (WDR4) complex. Emerging evidence suggests that the METTL1/WDR4 complex plays a role in brain development and disease pathogenesis. m7G has also been implicated in many types of tumorigeneses, including head, neck, lung, liver, colon, bladder, and teratoma. Investigations into m7G have found that this modification was crucial for tumor chemoresistance, vasculogenesis and prognosis. Determining the global changes in m7G levels is necessary to understand both the physiological and pathological states.

How it Works

Graphical representation of m7G quantification by dot blot assay.

Performance Data

Fig.1: Representative image of m7G-specific dot blot assay of RNA and plasma samples. Total RNA was isolated from the human lung cancer cell line of A431 and quantified by nanodrop, respectively (A). Plasma isolated from colorectal cancer (CRC) and normal health controls (B). m7G dot blot assay followed this protocol.